A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy

Disulfiram, a generic alcohol aversion drug, has promising preclinical activity against glioblastoma (GBM). This phase I study aims to evaluate its safety, maximum tolerated dose (MTD), pharmacodynamic effect, and preliminary efficacy when combined with adjuvant temozolomide in GBM patients after st...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-oncology 2016-06, Vol.128 (2), p.259-266
Hauptverfasser:	Huang, Jiayi, Campian, Jian L., Gujar, Amit D., Tran, David D., Lockhart, A. Craig, DeWees, Todd A., Tsien, Christina I., Kim, Albert H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Chemoradiotherapy Clinical Study Dacarbazine - analogs & derivatives Dacarbazine - therapeutic use Disulfiram - adverse effects Disulfiram - pharmacokinetics Disulfiram - therapeutic use Dose-Response Relationship, Drug Drug Repositioning Drug Therapy, Combination Female Glioblastoma - blood Glioblastoma - therapy Humans Male Medicine Medicine & Public Health Middle Aged Neurology Oncology Proteasome Endopeptidase Complex - blood Proteasome Endopeptidase Complex - drug effects Proteasome Inhibitors - adverse effects Proteasome Inhibitors - pharmacokinetics Proteasome Inhibitors - therapeutic use Supratentorial Neoplasms - blood Supratentorial Neoplasms - therapy Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!